Across TCGA pan-cancer cohorts, RNA5SP287 RNA is linked to patient survival in 2 of 34 cancer types, making it the most broadly survival-associated RNA5SP287 data layer.
The strongest signal is observed in esophageal carcinoma (ESCA), where higher RNA5SP287 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated RNA5SP287 expression acts as an unfavorable survival marker.
ESCA and STAD are the cancer types where RNA5SP287 RNA most reproducibly stratifies survival.